Liver cancer tumor is one of the most common liver malignant tumors in the world, among which hepatocellular carcinoma accounts for about 90% of primary liver cancer. In recent years, its incidence has been increasing rapidly in many major regions of the world, and it is also the second leading cause of tumor death in the world.In recent years, although our country liver cancer clinical early diagnosis and early treatment of patients, surgery and perioperative patient care technology improved, and part of the late primary liver cancer targeted therapy and the use of biological immunotherapy drugs, improve the majority of patients with clinical survival time, but still because of the current high incidence of liver cancer disease, high surgical recurrence rate and relatively limited drug treatment strategy, its future overall survival rate is still relatively not idealTherefore, it is very important to find new methods or new ways to treat liver cancer. In this paper explores one of the mechanisms of liver cancer occurrence, and understand and analyze liver cancer through credit analysis.analyze the regulation of miRNA-370-3p on mdm 2-p53 pathway in hepatocellular carcinoma. Methods Through QuickGo database, David database, String, Cytoscape, BGI, the mechanism of mdm 2 regulating the mdm 2, then cRNA, and the ceRNA regulation mechanism of abnormal mdm 2 gene expression by bioinformatic analysis.

Di Lu, Yueyong Li. Analysis of the regulation of the mdm 2-p53 pathway by MiRNA-370-3P in hepatocellular carcinoma. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 2: 1-8. https://doi.org/10.25236/IJFM.2024.060201.

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2021, 71(3):209-249.

[2] Cao Mao, Li Hui, Sing Ding, et al. Cancer burden of major cancers in China: a need for sustainable actions[J] . Cancer Communications, 2020, 40(5):205-210.

[3] Zaky M A , Hanafy M S , BordinyE M M , et al. Association between TP53 and MDM2 Gene Polymorphisms and Risk of Hepatocellular Carcinoma in Hepatitis C Virus among Egyptian Populations[J]. Asian Journal of Research in Biochemistry, 2020, 148-156.

[4] Sorop A, Con D, Co F, et al. Exosomal microRNAs As biomarkers and therapeutic targets for hepatocellular carcinoma  [J] . IntJMolSci, 2021, 22(9):4997

[5] Zeng He, Chen Wu, Zheng Rui, et al. Changing cancer survival in China during a pooled analysis of 17 population  based  cancer registries[J] . LancetGlob Health, 2018, 6(5): e555 - e567

[6] Jin Yan and Fu Songbin. Progress in the relationship between tumor suppressor gene P53 and tumor and gene therapy [J]. Foreign Medical Genetics Book 2001 24 (4): 201-206

[7] Azer S .MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?[J].Journal of Clinical Medicine,2018,7(4):64.

[8] Yuanfeng Z, Kuifeng W, Ni Z, et al. Butein activates p53 in hepatocellular carcinoma cells via blocking MDM2-mediated ubiquitination.[J].OncoTargets and therapy, 2018,112007-2015.

[9] Chao N, Linlin W, Weijian Y, et al. CCAT2 contributes to hepatocellular carcinoma progression via inhibiting miR-145 maturation to induce MDM2 expression.[J].Journal of cellular physiology, 2020, 235(9):6307-6320.

[10] Rui S, Zirong L. RPL15 promotes hepatocellular carcinoma progression via regulation of RPs-MDM2-p53 signaling pathway[J].Cancer Cell International, 2022,22(1):150-150.

[11] Jingyi C, Fangxin Z, Hongxin Y, et al. Gentian violet induces apoptosis and ferroptosis via modulating p53 and MDM2 in hepatocellular carcinoma.[J].American journal of cancer research, 2022, 12(7):3357-3372.

[12]Taniue Kenzui, Akimitsu Nobuyoshi.  The Functions and Unique Features of LncRNAs in Cancer Development and Tumorigenesis [J].  International Journal of Molecular Sciences. 2021 (2)

[13] Wangrui Qi, Long Xiao, Ningning Zhou, Dongni Chen, Meiyin Zhang , ZheshengWen, Lanjun Zhang, Fazhong He, Zhilin Zhou, Shijuan Mai, Huiyun Wang. Lnc-GAN1 expression is associated with good survival and suppresses tumor progression by sponging mir-26a-5p to activate PTEN signaling in non-small cell lung cancer [J]. Journal of Experimental & Clinical Cancer Research. 2021(1)

[14] Huang Yue and CAI Jianming. MDM 2 function and its Regulation Mechanism [J]. Foreign Medical Oncology Volume 2004 31 (5): 336-339.

[15] Chen Shaozheng, Kejun Li. HOXD-AS1 facilitates cell migration and invasion as an oncogenic lncRNA by competitively binding to miR-877-3p and upregulating FGF2 in human cervical cancer. [J]. BMC cancer. 2020 (1)

[16] Wang Sun, Yang Ming. Exosomal microRNAs as diagnostic and the rapeutic biomarkers in nonmalignant liver diseases [J].Arch PharmRes, 2021, 44(6):574-587.

[17] He X, Zou K. MiRNA-96-5p contributed to the proliferation of gastric cancer cells by targeting FOXO3 [J]. Biochem, 2020, 167:101-108. 

[18] Chen Lanni, Zhang Huijiao, Xu Xuejiao, Xu Ke, Zhu Min. MiR-370-3P inhibits proliferation of human articular chondrocytes by regulating JAK2/STAT5B signaling pathway [J]. Journal of Third Military Medical University, 2021, 43(13):1212-1218.